Author of

• 35790

  +

  P60 - Tumor Biology and Systems Biology - Basic and Translational Science - Immune Bio (ID 198)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Tumor Biology and Systems Biology - Basic and Translational Science
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 35792

    +

    P60.02 - Insight Into Intestinal Microbiome in NSCLC Patients: More Personalized Immunotherapy in the Crosshairs (ID 1344)

    00:00 - 00:00  |  Presenting Author(s): Anna Grenda
    • Abstract
    • Slides

    Introduction
    

    Intestinal bacteria are associated with the functioning of the immune system. The composition of the intestinal microbiome may be associated with the effectiveness of anti-PD-1 or anti-PD-L1 immunotherapy in patients with cancers including non-small cell lung cancer (NSCLC).

    Methods
    

    We investigated (from September 2018 to December 2019) fecal samples taken prior to immunotherapy with anti-PD-1 or anti-PD-L1 antibodies from 26 NSCLC patients. In 17 (65%) patients adenocarcinoma and in 9 (35%) squamous cell carcinoma was diagnosed.

    We isolated DNA from fecal samples and conducted a microbiome analysis using next generation sequencing (NGS) with utility of Illumina MiSeq device. The 16S rRNA metagenomics profiling was made using Qiime 2.0 software. Statistic were conducted with MedCalc software.

    Results
    

    Eighth (31%) patients had disease stabilization, 4 (15%) partial response and 14 (54%) disease progression. Higher percentage of Clostridiaceae 1 and Streptococcaceae was observed in patients with disease progression compared to patients with stable disease or partial response to immunotherapy (p=0.007 and p=0.06 respectively).

    Median of progression free survival (PFS) in studied group treated with immunotherapy (pembrolizumab, nivolumab or atezolizumab) was 20 weeks (95%CI: 8.0 – 72.0). We observed significant higher risk of disease progression in patients with high burden of Micrococcaceaes, Streptococcaceae and Clostridiaceae 1 compared to patients without presence of this bacteria in fecal samples (HR=0.3061, 95%CI: 0.0893-1.0489, p=0.05; HR=0.1605, 95%CI: 0.0470-0.5484, p=0.0035 and HR=0.1849, 95%CI: 0.0518-0.6601, p=0.0093, respectively).

    Conclusion
    

    Our pilot study showed that composition of fecal microbiome, especially high burden of Micrococcaceaes, Streptococcaceae and Clostridiaceae, could influence the effectiveness of immunotherapy in NSCLC patients.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.